Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer

doi:10.16139/j.1007-9610.2021.01.007

Abstract

CLC Number:

CHENG Guozhu, CAI Guoxiang. Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 34-37.

References 27

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2]	Franko J, Shi Q, Goldman CD, et al. Treatment of co-lorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3):263-267. doi: 10.1200/JCO.2011.37.1039 pmid: 22162570
[3]	Mo S, Cai G. Multidisciplinary treatment for colorectal peritoneal metastases: review of the literature[J]. Gastroenterol Res Pract, 2016, 2016:1516259.
[4]	Aoyagi T, Terracina KP, Raza A, et al. Current treatment options for colon cancer peritoneal carcinomatosis[J]. World J Gastroenterol, 2014, 20(35):12493-12500.
[5]	Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer[J]. J Clin Med, 2018, 7(12):567.
[6]	Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer[J]. Ann Surg Oncol, 2008, 15(9):2426-2432. doi: 10.1245/s10434-008-9966-2 pmid: 18521686
[7]	Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial[J]. Eur J Cancer, 2016, 53:155-162. doi: 10.1016/j.ejca.2015.09.017 pmid: 26751236
[8]	Quenet J, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7[J]. J Clin Oncol, 2018, 36(18 suppl):LBA3503.
[9]	Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO,MOS, SSO and TOS[J]. Ann Oncol, 2018, 29(1):44-70. doi: 10.1093/annonc/mdx738 pmid: 29155929
[10]	赵志勋, 裴炜, 熊斌, 等. 结直肠癌腹膜转移诊治中国专家意见(2017)[J]. 中华结直肠疾病电子杂志, 2017, 6(5):360-366.
[11]	Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer[J]. J Surg Oncol, 2020, 121(8):1298-1305.
[12]	Steffen T, Eden J, Bijelic L, et al. Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: consensus on decision making among international experts[J]. Clin Colorectal Cancer, 2020, 19(4):277-284.
[13]	Qiu C, Li Y, Liang X, et al. A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with raltitrexed[J]. Biomed Pharmacother, 2017, 92:149-156.
[14]	Roy P, Canet-Jourdan C, Annereau M, et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: preclinical models to improve HIPEC[J]. Int J Pharm, 2017, 531(1):143-152.
[15]	Ubink I, Bolhaqueiro ACF, Elias SG, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy[J]. Br J Surg, 2019, 106(10):1404-1414. doi: 10.1002/bjs.11206 pmid: 31197820
[16]	Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase Ⅱ/Ⅲ trial[J]. Int J Cancer, 2010, 127(9):2209-2221.
[17]	Jordan K, Luetkens T, Gog C, et al. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase Ⅱ study-AIO SUP-0108[J]. Eur J Cancer, 2016, 63:127-134. doi: 10.1016/j.ejca.2016.05.004 pmid: 27314448
[18]	Gong Q, Song C, Wang X, et al. Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis[J]. Exp Biol Med (Maywood), 2020, 245(6):542-551.
[19]	Frøysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in co-lorectal peritoneal metastasis: results from the immunoPeCa phase 1 trial[J]. Ann Surg Oncol, 2017, 24(7):1916-1922. doi: 10.1245/s10434-017-5814-6 pmid: 28224367
[20]	Frøysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis[J]. Eur J Surg Oncol, 2021, 47(1):134-138. doi: 10.1016/j.ejso.2019.04.014 pmid: 31036394
[21]	Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressu-rized aerosol as an alternative to liquid solution: first evidence for efficacy[J]. Ann Surg Oncol, 2014, 21(2):553-559.
[22]	Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377.
[23]	Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis[J]. Colorectal Dis, 2016, 18(4):364-371. doi: 10.1111/codi.13130 pmid: 26400556
[24]	Siebert M, Alyami M, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy(PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. a single center comparative study[J]. Eur J Surg Oncol, 2021, 47(1):139-142.
[25]	Teixeira Farinha H, Grass F, Labgaa I, et al. Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy[J]. J Cancer, 2018, 9(1):13-20. doi: 10.7150/jca.21460 pmid: 29290765
[26]	Larbre V, Alyami M, Mercier F, et al. No renal toxicity after repeated treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with unresectable peritoneal metastasis[J]. Anticancer Res, 2018, 38(12):6869-6875.
[27]	Girshally R, Demtroder C, Albayrak N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. World J Surg Oncol, 2016, 14(1):253. pmid: 27678344

Study on intraperitoneal chemotherapy in treatment of peritoneal metastatic colorectal cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 27

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHENG Minhua, MA Junjun. Laparoscopic colorectal surgery 30 years in China: what we learned [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 181-185.
[2]	SUN Yueming, ZHANG Dongsheng. Controversy over the medial border of lymph node dissection during CME/D3 surgery of right colon cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 202-207.
[3]	YIN Jianguang, ZONG Yaping, SHEN Xiaohui, ZHAO Jingkun, LU Aiguo. Analysis of treatment and prognosis of synchronous multiple primary colorectal cancer: a report of 39 cases [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 540-544.
[4]	XU Zifeng, ZONG Yaping, LU Aiguo. Neoadjuvant therapy in patients with locally advanced colon cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 266-270.
[5]	BAO Quan, XING Baocai. Surgical treatment strategy for complex bilateral multiple liver metastases of colorectal carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130.
[6]	SHAO Jiazhe, ZHOU Guoqiang, GUO Jian, LIU Kun, ZHAO Ren. A retrospective study on single-incision laparoscoic surgery for right colonic cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 70-75.
[7]	LIU Shiguang, ZHAO Jingkun, LU Aiguo, MAO Zhihai. Expression of chemokine CXCL5 and programme death ligand 1 in colorectal cancer tissues are associated with prognosis of patients [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 543-549.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 277-280.
[9]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 290-296.
[10]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 312-317.
[11]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 318-324.
[12]	WU Chunxiao, GONG Yangming, GU Kai, PANG Yi, BAO Pingping, WANG Chunfang, SHI Liang, XIANG Yongmei, DOU Jianming, FU Chen, SHI Yan. Colorectal cancer incidence and mortality in Shanghai 2016 and trend analysis 2002—2016 [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 325-335.
[13]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 281-284.
[14]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 297-299.
[15]	. [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 300-304.